Prosecution Insights
Last updated: April 19, 2026
Application No. 18/248,573

Attenuated Porcine Epidemic Diarrhea Virus

Final Rejection §112
Filed
Apr 11, 2023
Examiner
SALVOZA, M FRANCO G
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zoetis Services LLC
OA Round
2 (Final)
69%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
98%
With Interview

Examiner Intelligence

Grants 69% — above average
69%
Career Allow Rate
414 granted / 600 resolved
+9.0% vs TC avg
Strong +29% interview lift
Without
With
+29.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
46 currently pending
Career history
646
Total Applications
across all art units

Statute-Specific Performance

§101
8.4%
-31.6% vs TC avg
§103
31.0%
-9.0% vs TC avg
§102
12.1%
-27.9% vs TC avg
§112
26.8%
-13.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 600 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. Claims 1-18, 25-28 are canceled. Claims 19-24, 39 are amended. It is noted that claims 29, 38 are also amended but do not contain the proper status identifier; claim 38 does not have the proper amendment marking for the comma (See MPEP 714). Claims 19-24, 29-39 are under consideration. Claim Objections 2. (previous objection; maintained as to claims 19, 34; withdrawn as to claims 22-26, 28, 38, 39) Claims 19, 34 are objected to because of informalities. Applicant contends: the claims are amended. Applicant’s arguments are considered and found persuasive as to claims 22-26, 28, 38, 39. The previous objections do not appear to have been addressed as to claims 19 (the claim should recite "ORF-3" as well as "ORF-2/ORF-3" to be internally consistent), 34 (For improved clarity, claim 34 should recite "administering colostrum from a sow … according to claim 29 to said piglet". See the objections in the previous Office Action. The objection is maintained as to claims 19, 34. Claim Rejections - 35 USC § 112 3. (previous rejection, withdrawn) Claims 19-23, 26, 29-39 were rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. Applicant contends: the claims are amended. In view of applicant’s amendments, the rejection is withdrawn. 4. (previous rejection, withdrawn) Claim 25 was rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. Applicant contends: the claims are amended. In view of applicant’s amendments, the rejection is withdrawn. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. (previous rejection, withdrawn as to claims 20, 27, 28; maintained as to claims 22, 33, 35) Claims 22, 33, 35 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. See claims 22, 33, 35 as submitted 2/4/2026. Applicant contends: the claims have been amended. Applicant’s arguments are considered and found persuasive as to claims 20, 27, 28. See the rejection in the previous Office Action as to claims 22, 33, 35. The rejections do not appear to have been addressed. The rejection is maintained for reasons of record. Conclusion 6. Claims 20, 21, 23, 24, 29-32, 36-39 are objected to for depending on objected to and rejected claims. 7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to M FRANCO G SALVOZA whose telephone number is (571)272-4468. The examiner can normally be reached M-F 8:00 to 5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone can be reached at 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /M FRANCO G SALVOZA/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Apr 11, 2023
Application Filed
Nov 01, 2025
Non-Final Rejection — §112
Feb 04, 2026
Response Filed
Feb 21, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599656
METHODS FOR TREATING HPV-ASSOCIATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12577541
METHOD FOR LARGE-SCALE PREPARATION OF PURIFIED PREPARATION OF RECOMBINANT LENTIVIRAL VECTOR AT GMP GRADE
2y 5m to grant Granted Mar 17, 2026
Patent 12564643
POLYMERIC NANOVACCINES AND USES THEREOF
2y 5m to grant Granted Mar 03, 2026
Patent 12564663
MICROPOROUS ANNEALED PARTICLE GEL SYSTEM
2y 5m to grant Granted Mar 03, 2026
Patent 12558418
EGG ALLERGY ANTIGEN
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
69%
Grant Probability
98%
With Interview (+29.2%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 600 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month